← 返回前沿论文

NK 细胞介导静脉注射 BCG 对小鼠肺转移的预防效果

英文原题:NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice.

PubMed 2025/08/02(内容时间) Cancer Gene Ther Q1 · IF 6.4(JCR 2025)

研究概要

肺转移常起源于原发肿瘤,包括膀胱癌,是重要的不良预后因素。

中文摘要

肺转移常起源于原发性肿瘤,包括膀胱癌,并且是一个关键的负性预后因素。自然杀伤(NK)细胞已被证明在控制转移中发挥重要作用。因此,肿瘤细胞进化出了特定机制来逃逸NK细胞介导的免疫监视,从而促进转移和对免疫治疗的抵抗。在本研究中,我们利用小鼠模型探讨了静脉注射卡介苗(BCG)在预防膀胱癌细胞肺转移方面的预防性和治疗性潜力。我们证明,预防性给予BCG可显著降低肿瘤负荷并延长生存期,这很大程度上是通过NK细胞激活实现的。然而,当对已形成的肿瘤给予BCG治疗时则无效,这可能是由于肿瘤驱动的免疫逃逸机制。我们的结果揭示了干扰素-γ(IFN-)对肿瘤抵抗的贡献。暴露于IFN- 的肿瘤细胞在体内对BCG更具抵抗力,这与免疫检查点分子的过表达相关,而在肿瘤细胞中破坏IFN- 信号通路则部分恢复了BCG的治疗疗效。我们的发现凸显了理解肿瘤免疫逃逸机制的重要性,并提示BCG可能是预防膀胱癌肺转移的一种有前景的治疗方法。

展开英文摘要原文

Lung metastases frequently arise from primary tumors, including bladder cancer, and represent a critical negative prognostic factor. Natural Killer (NK) cells have shown to play a vital role in controlling metastasis. Consequently, tumor cells have evolved specific mechanisms to evade NK cell-mediated immune surveillance, promoting metastasis and resistance to immunotherapy. In this study, we investigated the prophylactic and therapeutic potential of intravenous Bacillus Calmette-Guerin (BCG) in preventing lung metastases from bladder cancer cells using a murine model. We demonstrated that prophylactic BCG administration significantly reduced tumor burden and prolonged survival, largely through NK cell activation. However, BCG treatment was ineffective when administered over established tumors, likely due to tumor-driven immune evasion mechanisms. Our results revealed the contribution of interferon-gamma (IFN- ) to tumor resistance. Tumor cells exposed to IFN- were more resistant to BCG in vivo, which correlated with the overexpression of immune checkpoint molecules, whereas disruption of the IFN- signaling pathway in tumor cells partially restored the therapeutic efficacy of BCG. Our findings highlight the importance of understanding tumor immune escape mechanisms and suggest that BCG could be a promising treatment for preventing lung metastases in bladder cancer.

论文信息

作者
Guerrero C、Casal M、Alierta C、Moreo E、Araujo-Voces M、Uranga S、Gómez AB、Martín C
第一作者单位
Grupo de Genética de Micobacterias, Departamento de Microbiología y Medicina Preventiva, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragon, Zaragoza, Spain.Spain
通讯作者单位
Grupo de Genética de Micobacterias, Departamento de Microbiología y Medicina Preventiva, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragon, Zaragoza, Spain. naguilo@unizar.es.Spain
期刊
Cancer gene therapy2025 Oct
原文标识
PubMed 40753303 · DOI 10.1038/s41417-025-00948-y